NEW YORK, Jan. 07, 2020 BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 07, 2020 BrainStorm Cell Therapeutics Inc.
Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced two additions to its leadership. Seasoned patent attorney Amy Mendel joins Vor as Chief Legal Officer and human resources executive Tania Philipp joins as Vice President of People. These experienced life sciences specialists continue to round out Vors management team as the company expands, develops its platform technology, and advances its pipeline of eHSC-based therapies.
Stem cells are the repair cells of your body. When there arent enough of them, or they arent working properly, chronic diseases can manifest and persist
Regenerative medicine, the most recent and emerging branch of medical science, deals with functional restoration of tissues or organs for the patient suffering from severe injuries or chronic diseaseconditions, in the state where bodies own regenerative responses do not suffice The spectacular progress in the field of stem cell research has laid the foundation for cell based therapies of disease which cannot be cured by conventional medicines. The indefinite self-renewal and potential to differentiate into other types of cells represent stem cells as frontiers of regenerative medicine
NEW YORK, Jan.
DURHAM, N.C. (PRWEB) January 06, 2020 A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM).
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch.
ROCKVILLE, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors,today announced the appointment of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing.
The reconstitution of the blood system in humans holds great therapeutic potential to treat many disorders, like blood cancers, sickle-cell anemia and others. Successful reconstitution requires the transplantation and engraftment of hematopoietic (or blood) stem cells (HSCs), which after reaching their niche, start producing all types of blood cells, including platelets, white and red blood cells. In current clinical practice, this is carried out by infusing HSCs obtained from a matched donor who is immunologically compatible with the patient in need (allogeneic transplantation), or by the expansion of the patient's own HSCs in the lab, and then re-infusing them back into the patient (ex-vivo, autologous transplantation)
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.
Recent Comments